-
Product Insights
NewNet Present Value Model: Medivir AB’s Fostroxacitabine Bralpamide Hydrochloride
Empower your strategies with our Net Present Value Model: Medivir AB's Fostroxacitabine Bralpamide Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inavolisib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inavolisib in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inavolisib in Metastatic Breast Cancer Drug Details: Inavolisib (GDC-0077) is...
-
Product Insights
NewCutaneous T-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Cutaneous T-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer that begins in white blood cells called T cells (T lymphocytes). These cells normally help body's germ-fighting immune system. In cutaneous T-cell lymphoma, the T cells develop abnormalities that make them attack the skin. Originating in T lymphocytes, it causes skin alterations like red, scaly patches or itchy plaques, progressing slowly...
-
Product Insights
NewHepatitis C – Drugs In Development, 2024
Empower your strategies with our Hepatitis C – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis C is a contagious viral infection affecting the liver. It spreads on contact with infected blood. It may be a mild condition or may be chronic, leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The offspring of...
-
Product Insights
NewBasal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery. The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in...
-
Product Insights
NewMycosis Fungoides – Drugs In Development, 2024
Empower your strategies with our Mycosis Fungoides – Drugs In Development, 2024 report and make more profitable business decisions. Mycosis fungoides is a rare type of non-Hodgkin lymphoma, specifically a subtype of cutaneous T-cell lymphoma (CTCL), which primarily affects the skin. It is characterized by the abnormal accumulation of malignant T-cells (a type of white blood cell) in the skin, leading to various skin symptoms and, in advanced stages, potential involvement of other organs. Mycosis fungoides is the most common type...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Remetinostat in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Remetinostat in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Remetinostat in Squamous Cell Carcinoma Drug Details: Remetinostat (SHP-141) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fimavacc in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fimavacc in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fimavacc in Head And Neck Cancer Drug Details:Fimavacc is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-0616 in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-0616 in Hypercholesterolemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MK-0616 in Hypercholesterolemia Drug Details:MK-0616 is under development for the treatment of atherosclerotic cardiovascular...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fostroxacitabine Bralpamide Hydrochloride in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fostroxacitabine Bralpamide Hydrochloride in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fostroxacitabine Bralpamide Hydrochloride in Hepatocellular CarcinomaDrug Details:fostroxacitabine bralpamide (MIV-818) is under...